NYSE - Nasdaq Real Time Price USD

Abbott Laboratories (ABT)

104.32 -0.55 (-0.52%)
As of 12:25 PM EDT. Market Open.
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
40,326,000.00
40,109,000.00
43,653,000.00
43,075,000.00
34,608,000.00
Cost of Revenue
18,107,000.00
17,975,000.00
19,142,000.00
18,537,000.00
15,003,000.00
Gross Profit
22,219,000.00
22,134,000.00
24,511,000.00
24,538,000.00
19,605,000.00
Operating Expense
15,864,000.00
15,656,000.00
16,149,000.00
16,113,000.00
14,248,000.00
Operating Income
6,355,000.00
6,478,000.00
8,362,000.00
8,425,000.00
5,357,000.00
Net Non Operating Interest Income Expense
-261,000.00
-252,000.00
-375,000.00
-490,000.00
-500,000.00
Other Income Expense
444,000.00
438,000.00
319,000.00
276,000.00
111,000.00
Pretax Income
6,538,000.00
6,664,000.00
8,306,000.00
8,211,000.00
4,968,000.00
Tax Provision
908,000.00
941,000.00
1,373,000.00
1,140,000.00
497,000.00
Net Income Common Stockholders
5,630,000.00
5,723,000.00
6,933,000.00
7,071,000.00
4,495,000.00
Diluted NI Available to Com Stockholders
5,630,000.00
5,723,000.00
6,933,000.00
7,071,000.00
4,495,000.00
Basic EPS
3.23
3.30
3.99
4.01
2.54
Diluted EPS
3.21
3.26
3.91
3.94
2.50
Basic Average Shares
1,739,616.25
1,734,076.36
1,737,795.02
1,764,082.19
1,771,230.27
Diluted Average Shares
1,748,484.25
1,749,000.00
1,764,000.00
1,789,000.00
1,786,000.00
Total Operating Income as Reported
6,355,000.00
6,478,000.00
8,362,000.00
8,425,000.00
5,357,000.00
Total Expenses
33,971,000.00
33,631,000.00
35,291,000.00
34,650,000.00
29,251,000.00
Net Income from Continuing & Discontinued Operation
5,630,000.00
5,723,000.00
6,933,000.00
7,071,000.00
4,495,000.00
Normalized Income
5,660,139.19
5,758,219.00
6,934,670.00
7,071,861.00
4,463,800.00
Interest Income
364,000.00
385,000.00
183,000.00
43,000.00
46,000.00
Interest Expense
625,000.00
637,000.00
558,000.00
533,000.00
546,000.00
Net Interest Income
-261,000.00
-252,000.00
-375,000.00
-490,000.00
-500,000.00
EBIT
7,163,000.00
7,301,000.00
8,864,000.00
8,744,000.00
5,514,000.00
EBITDA
10,405,000.00
10,544,000.00
12,131,000.00
12,282,000.00
8,841,000.00
Reconciled Cost of Revenue
16,812,000.00
16,698,000.00
17,888,000.00
17,046,000.00
13,808,000.00
Reconciled Depreciation
3,242,000.00
3,243,000.00
3,267,000.00
3,538,000.00
3,327,000.00
Net Income from Continuing Operation Net Minority Interest
5,630,000.00
5,723,000.00
6,933,000.00
7,071,000.00
4,471,000.00
Total Unusual Items Excluding Goodwill
-35,000.00
-41,000.00
-2,000.00
-1,000.00
8,000.00
Total Unusual Items
-35,000.00
-41,000.00
-2,000.00
-1,000.00
8,000.00
Normalized EBITDA
10,440,000.00
10,585,000.00
12,133,000.00
12,283,000.00
8,833,000.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-4,860.81
-5,781.00
-330.00
-139.00
800.00
12/31/2020 - 3/17/1980

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

MDT Medtronic plc
85.53
-0.13%
 
BSX Boston Scientific Corporation
74.23
-0.44%
 
SYK Stryker Corporation
331.88
-0.63%
 
DXCM DexCom, Inc.
131.71
-0.15%
 
EW Edwards Lifesciences Corporation
88.90
-1.35%
 
ALGN Align Technology, Inc.
270.51
-1.11%
 
PODD Insulet Corporation
185.67
+0.15%
 
ZBH Zimmer Biomet Holdings, Inc.
119.87
-1.12%
 
TMDX TransMedics Group, Inc.
138.80
+2.86%
 
PHG Koninklijke Philips N.V.
27.91
+1.64%